Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Phathom Pharmaceuticals Inc PHAT

Healthcare Biotechnology
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PHAT)

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

GlobeNewswire 7 days ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire 10 days ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

GlobeNewswire February 17, 2026

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

GlobeNewswire February 5, 2026

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 7, 2026

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 7, 2026

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire January 7, 2026

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

GlobeNewswire November 4, 2025

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 3, 2025
View More News ››

Opinion & Analysis (NDAQ:PHAT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PHAT)

PHAT ....3rd tap on the $10 Holla

Cheers !
Iseneschal - June 6, 2025

PHAT.... New targets to watch for

$10.63........... Then N.H.O.D $12.19 It has to stay above $9.56 GLTA
Iseneschal - June 6, 2025

PHAT.....$10.00 Holla ; )

LFG !!!!!!
Iseneschal - June 6, 2025

PHAT...last at $9.84

LFG !!!!!!!!!!!!!!!
Iseneschal - June 6, 2025

PHAT ....so far so good

Upside target is resistance at $9.62 Downside support is at $ 8.35 Trade accordingly
Iseneschal - June 6, 2025

PHAT ....start the drumroll....has to hold $8.53

Vols are declining Wait for the dip into the gap
Iseneschal - June 6, 2025
View more Bullboard ››

Mink Ventures Corp.

Mink Ventures Corp.

Mink Ventures Corporation engages in the acquisition, exploration, and development of mineral property interests in Canada ...
View More »

Podcasts